A citation-based method for searching scientific literature

Suzanne George, Qian Wang, Michael C Heinrich, Christopher L Corless, Meijun Zhu, James E Butrynski, Jeffrey A Morgan, Andrew J Wagner, Edwin Choy, William D Tap, Jeffrey T Yap, Annick D Van den Abbeele, Judith B Manola, Sarah M Solomon, Jonathan A Fletcher, Margaret von Mehren, George D Demetri. J Clin Oncol 2012
Times Cited: 169







List of co-cited articles
652 articles co-cited >1



Times Cited
  Times     Co-cited
Similarity


Efficacy and safety of regorafenib for advanced gastrointestinal stromal tumours after failure of imatinib and sunitinib (GRID): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
George D Demetri, Peter Reichardt, Yoon-Koo Kang, Jean-Yves Blay, Piotr Rutkowski, Hans Gelderblom, Peter Hohenberger, Michael Leahy, Margaret von Mehren, Heikki Joensuu,[...]. Lancet 2013
748
76

Efficacy and safety of sunitinib in patients with advanced gastrointestinal stromal tumour after failure of imatinib: a randomised controlled trial.
George D Demetri, Allan T van Oosterom, Christopher R Garrett, Martin E Blackstein, Manisha H Shah, Jaap Verweij, Grant McArthur, Ian R Judson, Michael C Heinrich, Jeffrey A Morgan,[...]. Lancet 2006
53

Efficacy and safety of imatinib mesylate in advanced gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Charles D Blanke, Annick D Van den Abbeele, Burton Eisenberg, Peter J Roberts, Michael C Heinrich, David A Tuveson, Samuel Singer, Milos Janicek,[...]. N Engl J Med 2002
47

Primary and secondary kinase genotypes correlate with the biological and clinical activity of sunitinib in imatinib-resistant gastrointestinal stromal tumor.
Michael C Heinrich, Robert G Maki, Christopher L Corless, Cristina R Antonescu, Amy Harlow, Diana Griffith, Ajia Town, Arin McKinley, Wen-Bin Ou, Jonathan A Fletcher,[...]. J Clin Oncol 2008
491
40

Gain-of-function mutations of c-kit in human gastrointestinal stromal tumors.
S Hirota, K Isozaki, Y Moriyama, K Hashimoto, T Nishida, S Ishiguro, K Kawano, M Hanada, A Kurata, M Takeda,[...]. Science 1998
37

Regorafenib (BAY 73-4506): a new oral multikinase inhibitor of angiogenic, stromal and oncogenic receptor tyrosine kinases with potent preclinical antitumor activity.
Scott M Wilhelm, Jacques Dumas, Lila Adnane, Mark Lynch, Christopher A Carter, Gunnar Schütz, Karl-Heinz Thierauch, Dieter Zopf. Int J Cancer 2011
730
30

Kinase mutations and imatinib response in patients with metastatic gastrointestinal stromal tumor.
Michael C Heinrich, Christopher L Corless, George D Demetri, Charles D Blanke, Margaret von Mehren, Heikki Joensuu, Laura S McGreevey, Chang-Jie Chen, Annick D Van den Abbeele, Brian J Druker,[...]. J Clin Oncol 2003
28

Progression-free survival in gastrointestinal stromal tumours with high-dose imatinib: randomised trial.
Jaap Verweij, Paolo G Casali, John Zalcberg, Axel LeCesne, Peter Reichardt, Jean-Yves Blay, Rolf Issels, Allan van Oosterom, Pancras C W Hogendoorn, Martine Van Glabbeke,[...]. Lancet 2004
26

PDGFRA activating mutations in gastrointestinal stromal tumors.
Michael C Heinrich, Christopher L Corless, Anette Duensing, Laura McGreevey, Chang-Jie Chen, Nora Joseph, Samuel Singer, Diana J Griffith, Andrea Haley, Ajia Town,[...]. Science 2003
25

A phase I dose-escalation study of regorafenib (BAY 73-4506), an inhibitor of oncogenic, angiogenic, and stromal kinases, in patients with advanced solid tumors.
Klaus Mross, Annette Frost, Simone Steinbild, Susanne Hedbom, Martin Büchert, Ulrike Fasol, Clemens Unger, Jörn Krätzschmar, Roland Heinig, Oliver Boix,[...]. Clin Cancer Res 2012
224
25

Long-term results from a randomized phase II trial of standard- versus higher-dose imatinib mesylate for patients with unresectable or metastatic gastrointestinal stromal tumors expressing KIT.
Charles D Blanke, George D Demetri, Margaret von Mehren, Michael C Heinrich, Burton Eisenberg, Jonathan A Fletcher, Christopher L Corless, Christopher D M Fletcher, Peter J Roberts, Daniela Heinz,[...]. J Clin Oncol 2008
672
23

Ponatinib inhibits polyclonal drug-resistant KIT oncoproteins and shows therapeutic potential in heavily pretreated gastrointestinal stromal tumor (GIST) patients.
Andrew P Garner, Joseph M Gozgit, Rana Anjum, Sadanand Vodala, Alexa Schrock, Tianjun Zhou, Cesar Serrano, Grant Eilers, Meijun Zhu, Julia Ketzer,[...]. Clin Cancer Res 2014
96
23

Molecular correlates of imatinib resistance in gastrointestinal stromal tumors.
Michael C Heinrich, Christopher L Corless, Charles D Blanke, George D Demetri, Heikki Joensuu, Peter J Roberts, Burton L Eisenberg, Margaret von Mehren, Christopher D M Fletcher, Katrin Sandau,[...]. J Clin Oncol 2006
556
23

Regorafenib monotherapy for previously treated metastatic colorectal cancer (CORRECT): an international, multicentre, randomised, placebo-controlled, phase 3 trial.
Axel Grothey, Eric Van Cutsem, Alberto Sobrero, Salvatore Siena, Alfredo Falcone, Marc Ychou, Yves Humblet, Olivier Bouché, Laurent Mineur, Carlo Barone,[...]. Lancet 2013
22

PDGFRA mutations in gastrointestinal stromal tumors: frequency, spectrum and in vitro sensitivity to imatinib.
Christopher L Corless, Arin Schroeder, Diana Griffith, Ajia Town, Laura McGreevey, Patina Harrell, Sharon Shiraga, Troy Bainbridge, Jason Morich, Michael C Heinrich. J Clin Oncol 2005
548
22

Acquired resistance to imatinib in gastrointestinal stromal tumor occurs through secondary gene mutation.
Cristina R Antonescu, Peter Besmer, Tianhua Guo, Knarik Arkun, Glory Hom, Beata Koryotowski, Margaret A Leversha, Philip D Jeffrey, Diann Desantis, Samuel Singer,[...]. Clin Cancer Res 2005
568
21

Gastrointestinal stromal tumours: origin and molecular oncology.
Christopher L Corless, Christine M Barnett, Michael C Heinrich. Nat Rev Cancer 2011
479
21

Heterogeneity of kinase inhibitor resistance mechanisms in GIST.
B Liegl, I Kepten, C Le, M Zhu, G D Demetri, M C Heinrich, C D M Fletcher, C L Corless, J A Fletcher. J Pathol 2008
283
21


Phase III randomized, intergroup trial assessing imatinib mesylate at two dose levels in patients with unresectable or metastatic gastrointestinal stromal tumors expressing the kit receptor tyrosine kinase: S0033.
Charles D Blanke, Cathryn Rankin, George D Demetri, Christopher W Ryan, Margaret von Mehren, Robert S Benjamin, A Kevin Raymond, Vivien H C Bramwell, Laurence H Baker, Robert G Maki,[...]. J Clin Oncol 2008
693
20

One vs three years of adjuvant imatinib for operable gastrointestinal stromal tumor: a randomized trial.
Heikki Joensuu, Mikael Eriksson, Kirsten Sundby Hall, Jörg T Hartmann, Daniel Pink, Jochen Schütte, Giuliano Ramadori, Peter Hohenberger, Justus Duyster, Salah-Eddin Al-Batran,[...]. JAMA 2012
573
19

Clinical evaluation of continuous daily dosing of sunitinib malate in patients with advanced gastrointestinal stromal tumour after imatinib failure.
S George, J Y Blay, P G Casali, A Le Cesne, P Stephenson, S E Deprimo, C S Harmon, C N J Law, J A Morgan, I Ray-Coquard,[...]. Eur J Cancer 2009
244
18

Regorafenib (BAY 73-4506) in advanced colorectal cancer: a phase I study.
D Strumberg, M E Scheulen, B Schultheis, H Richly, A Frost, M Büchert, O Christensen, M Jeffers, R Heinig, O Boix,[...]. Br J Cancer 2012
169
17

Effect of the tyrosine kinase inhibitor STI571 in a patient with a metastatic gastrointestinal stromal tumor.
H Joensuu, P J Roberts, M Sarlomo-Rikala, L C Andersson, P Tervahartiala, D Tuveson, S Silberman, R Capdeville, S Dimitrijevic, B Druker,[...]. N Engl J Med 2001
17

Two hundred gastrointestinal stromal tumors: recurrence patterns and prognostic factors for survival.
R P DeMatteo, J J Lewis, D Leung, S S Mudan, J M Woodruff, M F Brennan. Ann Surg 2000
17

KIT mutations and dose selection for imatinib in patients with advanced gastrointestinal stromal tumours.
Maria Debiec-Rychter, Raf Sciot, Axel Le Cesne, Marcus Schlemmer, Peter Hohenberger, Allan T van Oosterom, Jean-Yves Blay, Serge Leyvraz, Michel Stul, Paolo G Casali,[...]. Eur J Cancer 2006
608
15

Adjuvant imatinib mesylate after resection of localised, primary gastrointestinal stromal tumour: a randomised, double-blind, placebo-controlled trial.
Ronald P Dematteo, Karla V Ballman, Cristina R Antonescu, Robert G Maki, Peter W T Pisters, George D Demetri, Martin E Blackstein, Charles D Blanke, Margaret von Mehren, Murray F Brennan,[...]. Lancet 2009
865
15

Gastrointestinal stromal tumors: pathology and prognosis at different sites.
Markku Miettinen, Jerzy Lasota. Semin Diagn Pathol 2006
15

Resumption of imatinib to control metastatic or unresectable gastrointestinal stromal tumours after failure of imatinib and sunitinib (RIGHT): a randomised, placebo-controlled, phase 3 trial.
Yoon-Koo Kang, Min-Hee Ryu, Changhoon Yoo, Baek-Yeol Ryoo, Hyun Jin Kim, Jong Jin Lee, Byung-Ho Nam, Nikhil Ramaiya, Jyothi Jagannathan, George D Demetri. Lancet Oncol 2013
107
15

Crenolanib inhibits the drug-resistant PDGFRA D842V mutation associated with imatinib-resistant gastrointestinal stromal tumors.
Michael C Heinrich, Diana Griffith, Arin McKinley, Janice Patterson, Ajia Presnell, Abhijit Ramachandran, Maria Debiec-Rychter. Clin Cancer Res 2012
137
15

New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1).
E A Eisenhauer, P Therasse, J Bogaerts, L H Schwartz, D Sargent, R Ford, J Dancey, S Arbuck, S Gwyther, M Mooney,[...]. Eur J Cancer 2009
14

Correlation of computed tomography and positron emission tomography in patients with metastatic gastrointestinal stromal tumor treated at a single institution with imatinib mesylate: proposal of new computed tomography response criteria.
Haesun Choi, Chuslip Charnsangavej, Silvana C Faria, Homer A Macapinlac, Michael A Burgess, Shreyaskumar R Patel, Lei L Chen, Donald A Podoloff, Robert S Benjamin. J Clin Oncol 2007
998
14


Long-term follow-up results of the multicenter phase II trial of regorafenib in patients with metastatic and/or unresectable GI stromal tumor after failure of standard tyrosine kinase inhibitor therapy.
E Ben-Ami, C M Barysauskas, M von Mehren, M C Heinrich, C L Corless, J E Butrynski, J A Morgan, A J Wagner, E Choy, J T Yap,[...]. Ann Oncol 2016
48
29

Correlation of kinase genotype and clinical outcome in the North American Intergroup Phase III Trial of imatinib mesylate for treatment of advanced gastrointestinal stromal tumor: CALGB 150105 Study by Cancer and Leukemia Group B and Southwest Oncology Group.
Michael C Heinrich, Kouros Owzar, Christopher L Corless, Donna Hollis, Ernest C Borden, Christopher D M Fletcher, Christopher W Ryan, Margaret von Mehren, Charles D Blanke, Cathryn Rankin,[...]. J Clin Oncol 2008
404
13

Polyclonal evolution of multiple secondary KIT mutations in gastrointestinal stromal tumors under treatment with imatinib mesylate.
Eva Wardelmann, Sabine Merkelbach-Bruse, Katharina Pauls, Nadja Thomas, Hans-Ulrich Schildhaus, Thomas Heinicke, Nicola Speidel, Torsten Pietsch, Reinhard Buettner, Daniel Pink,[...]. Clin Cancer Res 2006
257
13

Regorafenib for patients with hepatocellular carcinoma who progressed on sorafenib treatment (RESORCE): a randomised, double-blind, placebo-controlled, phase 3 trial.
Jordi Bruix, Shukui Qin, Philippe Merle, Alessandro Granito, Yi-Hsiang Huang, György Bodoky, Marc Pracht, Osamu Yokosuka, Olivier Rosmorduc, Valeriy Breder,[...]. Lancet 2017
13

A multicenter phase II study of pazopanib in patients with advanced gastrointestinal stromal tumors (GIST) following failure of at least imatinib and sunitinib.
K N Ganjoo, V M Villalobos, A Kamaya, G A Fisher, J E Butrynski, J A Morgan, A J Wagner, D D'Adamo, A McMillan, G D Demetri,[...]. Ann Oncol 2014
52
23

Phase III study of nilotinib versus best supportive care with or without a TKI in patients with gastrointestinal stromal tumors resistant to or intolerant of imatinib and sunitinib.
P Reichardt, J-Y Blay, H Gelderblom, M Schlemmer, G D Demetri, B Bui-Nguyen, G A McArthur, S Yazji, Y Hsu, I Galetic,[...]. Ann Oncol 2012
82
14

Biology of gastrointestinal stromal tumors.
Christopher L Corless, Jonathan A Fletcher, Michael C Heinrich. J Clin Oncol 2004
820
12

Risk of recurrence of gastrointestinal stromal tumour after surgery: an analysis of pooled population-based cohorts.
Heikki Joensuu, Aki Vehtari, Jaakko Riihimäki, Toshirou Nishida, Sonja E Steigen, Peter Brabec, Lukas Plank, Bengt Nilsson, Claudia Cirilli, Chiara Braconi,[...]. Lancet Oncol 2012
494
12

NCCN Task Force report: update on the management of patients with gastrointestinal stromal tumors.
George D Demetri, Margaret von Mehren, Cristina R Antonescu, Ronald P DeMatteo, Kristen N Ganjoo, Robert G Maki, Peter W T Pisters, Chandrajit P Raut, Richard F Riedel, Scott Schuetze,[...]. J Natl Compr Canc Netw 2010
704
12

Molecular Subtypes of KIT/PDGFRA Wild-Type Gastrointestinal Stromal Tumors: A Report From the National Institutes of Health Gastrointestinal Stromal Tumor Clinic.
Sosipatros A Boikos, Alberto S Pappo, J Keith Killian, Michael P LaQuaglia, Chris B Weldon, Suzanne George, Jonathan C Trent, Margaret von Mehren, Jennifer A Wright, Josh D Schiffman,[...]. JAMA Oncol 2016
152
12

Avapritinib in advanced PDGFRA D842V-mutant gastrointestinal stromal tumour (NAVIGATOR): a multicentre, open-label, phase 1 trial.
Michael C Heinrich, Robin L Jones, Margaret von Mehren, Patrick Schöffski, César Serrano, Yoon-Koo Kang, Philippe A Cassier, Olivier Mir, Ferry Eskens, William D Tap,[...]. Lancet Oncol 2020
59
20

Regorafenib as second-line therapy for intermediate or advanced hepatocellular carcinoma: multicentre, open-label, phase II safety study.
Jordi Bruix, Won-Young Tak, Antonio Gasbarrini, Armando Santoro, Massimo Colombo, Ho-Yeong Lim, Vincenzo Mazzaferro, Reiner Wiest, María Reig, Andrea Wagner,[...]. Eur J Cancer 2013
157
11

Outcome of patients with advanced gastro-intestinal stromal tumours crossing over to a daily imatinib dose of 800 mg after progression on 400 mg.
John R Zalcberg, Jaap Verweij, Paolo G Casali, Axel Le Cesne, Peter Reichardt, Jean-Yves Blay, Marcus Schlemmer, Martine Van Glabbeke, Michelle Brown, Ian R Judson. Eur J Cancer 2005
264
11

Heat shock protein 90 inhibition in imatinib-resistant gastrointestinal stromal tumor.
Sebastian Bauer, Lynn K Yu, George D Demetri, Jonathan A Fletcher. Cancer Res 2006
201
11


Safety and efficacy of imatinib (STI571) in metastatic gastrointestinal stromal tumours: a phase I study.
A T van Oosterom, I Judson, J Verweij, S Stroobants, E Donato di Paola, S Dimitrijevic, M Martens, A Webb, R Sciot, M Van Glabbeke,[...]. Lancet 2001
987
11

Combined inhibition of MAP kinase and KIT signaling synergistically destabilizes ETV1 and suppresses GIST tumor growth.
Leili Ran, Inna Sirota, Zhen Cao, Devan Murphy, Yuedan Chen, Shipra Shukla, Yuanyuan Xie, Michael C Kaufmann, Dong Gao, Sinan Zhu,[...]. Cancer Discov 2015
77
14


Co-cited is the co-citation frequency, indicating how many articles cite the article together with the query article. Similarity is the co-citation as percentage of the times cited of the query article or the article in the search results, whichever is the lowest. These numbers are calculated for the last 100 citations when articles are cited more than 100 times.